ENV515-3-2 Travoprost XR
Phase 2Small molecule
ENV515-3-2 Travoprost XR is one of 16 small molecule programs targeting Ocular Hypertension. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Alphagan
NovartisPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Azopt
NovartisPhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
Reference - LUMIGAN
AAmneal Pharmaceuticals, LLC
Phase 3
PRO-122
LLaboratorios Sophia S.A de C.V.
Phase 3
BOL-303259-X
BBausch & Lomb Incorporated
Phase 3
Phxa41
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Alcon Investigational Agent
AAlcon Research
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ENV515-3-2 Travoprost XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEnvisia Therapeutics